Monday - December 23, 2024
Goodwin Advises Ampersand Capital Partners in Acquisition of Nektar Therapeutics' PEG Supply Business and Manufacturing Facility
December 07, 2024
BOSTON, Massachusetts, Dec. 7 -- Goodwin, a law firm, issued the following news release:

The Private Equity and Life Sciences teams advised Ampersand Capital Partners in the acquisition of Nektar's (NASDAQ: NKTR) PEGylation reagent supply business and related commercial-scale manufacturing facility. The new Ampersand portfolio company will be branded Gannet BioChem and will continue to operate out of its facility in Huntsville, Alabama.

Ampersand Capital Partners is a m . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products